Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been here as long as most and I'm feel stupid for believing that this company was a winner. 4 years later, no word about Singapore, now we are trying to enter a new market because the first entry failed.
I am a software developer, if you give me 6 months I could prob write the same appli cation and work with a doctor on A1c prediction. What they have is nothing proprietary. Chan didn't event the formula to predict A1C
Did you not read the letter to shareholders PR? They are filing for FDA approval this summer after trials for a human CGM. Obviously you are not familiar with diabetes, but the PR explained it very clearly. Their platform works but the industry doesn't want BGMs which is what they were using. They want CGMs.
If you can't follow the logic on the pet market then I will ignore your posts like I do your buddy. Ask a veterinarians, read some studies, look up statistics its all there and very easy to find. there are millions of pets that need a CGM 3 or 4 times a year. The Abbott Libre proves the need, but they will not support animal health. For a veterinarian to use one they have to write a prescription to the pet owner who has to go to a pharmacy and pay full price (cant use insurance) then come back for another appointment with the Vet to put it on. Not to mention there is no software for the Veterinarian to use so they have to just literally look at the pet owners phone. My vet has used one before and he said while medically it is phenomenal to get the data it is not practical so he doesnt use them. He said that a pet CGM sold to veterinarians will literally be the standard of care. if Veterinarians are going to that extreme to use the Libre (which isn't even a CGM its a flash monitor that you have to scan or lose the data every 8 hours) and they dont even make money off it because they dont sell it then its pretty obvious all the information is right about this being a big success. Not to mention ALRT is partnering with an animal health company that obviously also sees the value and further validates the market and need.
They said in the letter to shareholders they are looking to launch the human CGM with their platform the end of next year, so this gives positive cashflow until then.
If you want to hate on the company and stock and plan go right ahead, but at least try to know what you are talking about.
The pet market won't cause the human market to consider us, it makes us a bigger joke. Let's crack the fish market and sell to restaurants to check the blood sugar of the salmon I ordered. Company is grasping at straws
That's what I was kinda getting at, the pet market is almost a cop out, just shifting markets because the human one was impossible to enter with the big boys around.
According to this article, FreeStyle Libre has been available and is a CGM, lasting up to 14 days before sensor replacement, and has been available since 2019. Even though, according to the article, Abbott doesn't support for pet use. But, it is being used.
Almost 5 years now. We went from huge hope in human application, to now pets. I'd sell my measley 1/4 million shares for 07 right now if someone would buy them. That way I could double my money and the buyer can hang on for dollarland.
FreeStyle Libre
You are looking at BGMs, that has nothing to do with CGMs
I found about 5 more that are out on the market directed for pet owners between $30-50.
So alrt is pretty late to every game. I've been here almost 5 years now. We clearly don't have the game changer we thought 4 years ago after the FDA approval
Just did a quick Google search and there already is a pet gcm on the market
https://www.chewy.com/alphatrak-2-blood-glucose-monitoring/dp/262434?utm_source=google-product&utm_medium=cpc&utm_campaign=hg&utm_content=AlphaTRAK&utm_term=&gclid=CjwKCAiA0KmPBhBqEiwAJqKK45VE59kxGKF6oavwpuZB3H3oCfbT-ZAlH1QWA8ZA8WdyIO8w1ihk8xoCWNMQAvD_BwE
A little bit of research would answer your question. There are only three CGM companies, Medtronic (who is all but out of the game), Dexcom, and Abbott. Medtronic and Dexcom CGMs cost hundreds of dollars a unit (over $300 I think) so they are priced out of animal health. The Abbott Libre is sold for around $60-$80 so it would be the only other option and that is why some veterinarians use it. The market research PR said 40% of veterinarians surveyed had tried it and you can find a ton of veterinarian articles and published papers on its use "off label".
There is a lot of information out there if you look. Abbott has said they will not support CGM's for animals, they will not sell to veterinarians, and they will deactivate accounts they find using it. They are spending hundreds of millions of dollars trying to win market share in the human market which is more lucrative because there are over 500 million diabetics and they would need buy a CGM every 2 weeks.
If you look at the animal numbers there are only 4 million and they use them 3-5 times a year. So for company like Abbott thats worth hundreds of BILLIONS of dollars i cant imagine its worth putting the time, money and effort into. But for a company like ALRT the chance to make a few hundred million a year is extremely worthwhile. It wouldn't be a drop in the bucket for Abbott revenue but it will make ALRT shareholders rich
048 and we're doing great! Next stop - 040
Yeah good point, why can't current gcm companies just stick there thing in a dog's arm and and call it a day. All they need is marketing to vet clinics. Their brands are already globally recognized so wouldn't be hard for them to sell.
Also makes you wonder why they haven't done this. Not enough continuous revenue,sounds like dogs just need it for a round of testing and that's it, so that maybe one time a year monitoring isn't profitable enough to spend the marketing dollars
Here as well. There are similar products (at least for human use) already on the market, and if the Pet angle truly has merit you can bet bigger players than ALRT are already on it with greater resources to "make it happen". I realize there are some who will be quick to point out ALRT's unique offerings in the marketplace, but that doesn't mean much as time marches on and cash continues to bleed without any revenues.
For myself, it's become a race between my tolerance to "hang on" for years on end with only a hope and nothing to show for it, and this company's eventual demise and share price moving into triple zeros. GLTUA
Gern - I didn't see anything on a new purchase offer, not that I plan on exercising any such rights. Especially, as you say, at no real discount. The last one at 05 hasn't gone anywhere. Still no revenues.
The longer this speculation goes with no REAL revenue deal, the greater our chances are to becoming bag holders. Been there, done that with other pennies like Airborne Wireless.
Been holding 250K shares of ALRT for years now, reluctant to put another penny into this based on no solid indication of ALRT making it. Have about $9K invested at this point, and that's enough kaching for this guy to put down on any "pure" roulette wheel spin. I realize others have much more invested - good for them. If it hits, they can realize more money. If it doesn't, they'll lose much more than I. GLTU!
Same here Rdizz.
Here we go again.
I would like to think that these purchase offers are just because ALRT is a good dude and wants to reward current holders. I am very hesitant to do this again. Last time didn't work out so great and the "discount" isn't much of a discount to me. What is the difference between a share and a "subscription right"? Any thoughts on this?
That was an excellent piece of information. I realize the negative impact of diabetics on pets. It is critical to stick to the insulin and feeding schedules that have been prescribed for the pet. It is also critical that your pet has a normal appetite while on insulin therapy, or you danger hypoglycemia (low blood sugar) if your pet is not consuming and absorbing enough carbohydrates to balance the action of insulin in eliminating sugars from the bloodstream. You will also need to check your pet's blood and urine sugar levels on a frequent basis. Regular checkups and testing by your veterinarian may be augmented by at-home monitoring of your pet's blood and urine glucose levels and administration of appropriate insulin.
Anyone notice 2 new job openings on their website, Head of Sales USA
( Remote) and Head of Managed Care USA (Remote)
Right, I've been about break even for 4 years, I'm shocked it's held up this long though
We're back to 05. Dollarland any day now!!!!
Updates to the page look great lastone. Thanks for doing that.
Happy New Year to everyone.
2017: Dollarland any day now!
2018: Dollarland any day now!
2019: Dollarland any day now!
2020: Dollarland any day now!
2021: Dollarland any day now!
And, I suppose....
2022: Dollarland any day now!
would be nice to update this page with this news, so people can see the development taking place, thanks
$ALRT
2022 looking great for ALRT, I believe patience will bring big rewards here!
$ALRT
Corporate Strategy
The long-term goal for our company is to trade on one of the two major exchanges, the NYSE or the Nasdaq. While we are not there yet, based on our internal revenue and earnings projections for 2022 we are evaluating a listing on the NYSE American (formerly the American Stock Exchange). It is early in the process, but we have started the conversation with an investment bank to ensure we are ready when conditions warrant the change.
We believe that throughout 2022 the market will recognize the value of ALRT as we continue to deliver on the items discussed in this letter and in previous press releases. In closing, I would like to thank all of our shareholders once again for your support and look forward to achieving many more major milestones in 2022.
wow!
thanks for bringing it to the boards attention...
sure looking like dollarland to me! glty, glta
This is big! Letter to shareholders PR just dropped:
SINGAPORE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today releases an open letter to shareholders from Chairman and Chief Executive Officer Sidney Chan. A copy of the letter is presented in this press release, the original can be found at https://alrt.com/investors/2021lettertoshareholders.
Dear Fellow Shareholders,
2021 has been a transformative year for ALRT within which we have accomplished many important milestones. Most notable is the formation of the animal health division. As discussed below, the successful launch of the GluCurve Pet CGM (Continuous Glucose Monitor) should lead to revenue, earnings, and positive cashflows in the second half of 2022. We have discussed partnership opportunities on the GluCurve Pet CGM with various interested pharmaceutical companies and have selected our top candidate and are targeting to finalize a definitive agreement by May 2022. Additionally, we have brought on key additions to the ALR Technologies corporate team, and we have laid the groundwork to revolutionize diabetes care in human health. I am grateful for the support of our current shareholders, and the interest we have received from potential institutional investors, investment funds, and retail investors alike.
Shareholders have asked how all the latest developments connect and fit into the company roadmap. So, I thought it prudent to discuss the following five topics to give a holistic overview of what we have accomplished, what we seek to accomplish in 2022, and why we have chosen this path to bring value to stakeholders.
Continuous Glucose Monitor
Human Health Initiative
Animal Health
Pharmaceutical Partnership
Corporate Strategy
Continuous Glucose Monitor
Our diabetes management solution was designed to solve the biggest problem in diabetes care: Clinical Inertia, the failure to advance therapy on a timely basis. Our competitors’ products are all dependent on patient self-management, which we believe to be a fundamental flaw. We have created the only diabetes management platform based on active patient management. Utilizing artificial intelligence (AI), the only FDA cleared Insulin Dose Adjustment for long and fast acting insulins, patent pending Predictive A1C, and many other unique features, we greatly reduce the time and effort needed from the care team, while improving the effectiveness of care for the patient and addressing clinical inertia. Clinical trials and pilot studies have shown a 1.2% reduction of A1C over 6 months. To put that in perspective, the CDC has said that a 1% reduction in A1C reduces microvascular complications from diabetes by 40%.
Essentially, we know our Diabetes Solution works well from the feedback and data we received from studies and trials. But while we believe we have the best-in-class platform, it is utilizing a Blood Glucose Meter (BGM) to collect data. BGMs and diabetes test strips are quickly becoming a thing of the past. The industry wants CGMs, which are the best-in-class hardware for checking blood sugar. The growing demand for CGMs has stifled our attempts to sell our system paired with BGMs to payers, despite the positive results we have documented.
Human Health Initiative
While CGM systems are the way of the future for diabetes care, only a small fraction of the 500 million plus diabetics are utilizing those available from the current manufacturers due to several reasons, but in our estimate, it is primarily because of price. The current monthly cost of a CGM system ranges from $108-$500+ while the average monthly cost of a BGM and strips is less than $30. We see this as the key barrier to CGM adoption and plan to offer the ALRT Diabetes Solution with CGMs to payers for a monthly price competitive to BGMs. We are seeking to begin trials on the CGM in the summer of 2022 and thereafter will expect to file for FDA clearance with a target launch date of Q4 2023 to Q1-2024.
Animal Health – GluCurve Pet CGM
While we are diligently working on commercialization in human health over the next two years, we have identified and executed on an immediate opportunity in animal health that we believe should produce positive cashflow in 2022. There is a desperate need in veterinary medicine for a better way of monitoring blood sugar levels in diabetic pets.
The current standard of care is for a veterinarian to perform an in-clinic glucose curve which consists of drawing blood from the pet every two hours to test in a BGM, and manually recording the blood sugar levels. This method is burdensome, costly, only produces 6-7 blood sugar readings, and most importantly often produces inaccurate results from the stress on the pet being crated in a clinic for 10-12 hours and constantly having its blood drawn.
When a pet is diagnosed with diabetes, insulin is given to regulate its blood sugar levels and an in-clinic glucose curve is performed. Starting doses are typically low for safety reasons so the veterinarian will adjust the dose, frequency, or type of insulin the pet is prescribed based on the results and then another glucose curve will be performed. This process repeats until the pet’s blood sugar is properly regulated, then it is recommended the pet return every 3-4 months for a maintenance in-clinic glucose curve to ensure continued blood sugar regulation by adjusting the insulin prescription as needed.
The GluCurve Pet CGM will replace the current in-clinic glucose curve method of testing and be used for maintenance 3-4+ times a year, along with the 2+ times typically needed on newly diagnosed pets. The GluCurve Pet CGM is not intended to be worn permanently in the same manner as a human.
We are often asked why the market research firm indicated a 97% adoption rate for the GluCurve and why we anticipate becoming the standard of care. The answer is really quite simple. The GluCurve is financially favorable for both the veterinarians and the pet owner to use over current methods. It greatly reduces the effort and time of the clinic, and avoids the stress put on the pet. More importantly the data it produces results in faster, more effective, and less expensive regulation of blood sugar in diabetic pets. To be blunt, it is a better and cheaper than current methods.
Another question that comes up is how do we ensure the GluCurve CGM stays on the pet or what happens if it falls off? Again, the answer is quite simple. Although the GluCurve is approved to use for up to 14 days, it is not required to be used for that length of time. In-clinic glucose curves produce up to 7 data points over 12 hours. The GluCurve provides 240 data points every 12 hours without elevated readings from stress and in the real-life home setting. Therefore, whether it is worn for 14 days or for 1 day it provides drastically more information to the veterinarian at a much more affordable price to the pet owner.
The GluCurve provides diabetic patient management unique to veterinary medicine. We have adapted our human health software to animal health allowing us to offer insulin dose suggestions and guidelines for different insulins sold by different companies, along with the ability to collect enormous amounts of data on how pets react to each insulin. All of which is very valuable to insulin manufacturers and pharmaceutical companies in the animal health space.
There are an estimated 2 million diabetic pets within immediate reach and the potential of an additional 2.5 million more around the world. With a need for 2+ units at the initial diagnosis and 3+ units for yearly maintenance, the revenue and earnings potential are very strong.
Pharmaceutical Partnership
The revenue stream, insulin data, and brand value for being the market leader in diabetes by selling the first and only pet CGM is all of great value to various animal health companies. We have received several expressions of interest in purchasing a stake in the GluCurve or even a controlling interest. While we can certainly go to market utilizing the major distributors in animal health for a low fee, we believe a partnership with a pharmaceutical company is the best path for three primary reasons.
1) It will provide ALRT with a large amount of working capital outside of the cashflow from product sales.
2) It will give veterinarians confidence and credibility coming from a large and trusted name in animal health.
3) By utilizing the established network a large animal health company has with veterinary clinics around the world, we will be able to sell more units to more regions at a faster rate.
Corporate Strategy
The long-term goal for our company is to trade on one of the two major exchanges, the NYSE or the Nasdaq. While we are not there yet, based on our internal revenue and earnings projections for 2022 we are evaluating a listing on the NYSE American (formerly the American Stock Exchange). It is early in the process, but we have started the conversation with an investment bank to ensure we are ready when conditions warrant the change.
We believe that throughout 2022 the market will recognize the value of ALRT as we continue to deliver on the items discussed in this letter and in previous press releases. In closing, I would like to thank all of our shareholders once again for your support and look forward to achieving many more major milestones in 2022.
Sidney Chan
Chairman and Chief Executive Officer
December 20, 2021
About ALR Technologies
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed a solution to assist veterinarians in determining the effectiveness of insulin and helping to identify the appropriate dose and frequency of administration for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.
ALR Technologies SG Pte. Ltd. is a wholly owned subsidiary of ALR Technologies Inc. On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Regarding ALR Technologies SG Pte. Ltd. Information can be found at https://sg.alrt.com.
Contact
Ken Robulak (US)
Phone: +1 (727) 736-3838
Anthony Ngai (Singapore)
Phone: +65 3129 2924
Email: ir@alrt.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain “forward-looking statements” as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking information, and the words “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect”, “intend”, “plan”, "postulates", "predict", “will”, “may” or similar expressions suggesting future conditions or events or the negative of these terms are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Specifically, but not limited to, there is no assurance that the Company will commercialize the GluCurve CGM in 2022, or thereafter, have revenues, earnings, and positive cashflows from the sale of the GluCurve CGM, partner with a pharmaceutical for the GluCurve CGM, commence trials for CGM for human health in 2022 or thereafter, file CGM for FDA clearance CGM for human health, or commercialize CGM for human health thereafter. The forward-looking statements included in this news release are made as of the date hereof. ALR Technologies disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Silver is down yet further. Buy more silver.
Coming from the guy that has been singing "Dollarland" any day now for the last 4+ years.
Charlie Munger always says most people shouldn't invest themselves because they don't have the temperament for it. Ihub has proven that thesis correct. I just ignore the emotional outbursts and nonsense from that guy, he doesn't think logically or have any business sense so you can't have a real discussion with him.
109 million float, with no toxic dilution in the history of the company, all funded by the CEO. But nice try.
Lmao! Whoa… 250,000?! Dang that’s like 25k as I’m sure you bought at .10 or higher too as you don’t seem too bright here. No wonder why you won’t sell at .05. You’ve lost half your tiny liquidity. You’re about 4 million shares short of myself buddy, and I’m not selling any until all you penny traders get out of this stock. Good luck to you and your whopping 250k shares! Lmao!
10 billion authorized and $100,000,000 in accumulated deficit? Total diluted POS, last one out turn the lights off.
for a difference from your POS this one is current with wealthy CEO and big things coming
What a dilutive POS, heading to .0001, last one here turn the lights out on this bloated pig.
LOL. What about my other 250K shares? Wanna buy them at $0.10? I sell them to you. I'll tell you what... I'll buy YOUR whole allotment of 100 shares at 035 - that'll be your opportunity to get out. GLTU
In years past I understand ALRT not getting a lot of love and attention because of the unknowns surrounding when sales will come in, but now that we have a pretty firm timeline from their PRs and investors presentation I think we'll catch some wind and see a nice rise in volume and price over the coming months
Looking good bud, lots of interest coming here
ALRT
It's interesting that the MMs are completing most of the trades between the bid and the ask, GTSM is keeping the spread at .05/.06 but filling orders all over the place in between.
A lot of upcoming catalysts between now and the June launch date, but it's been good to see the volume come in yesterday and today. I'm sure the stock will get a lot more attention the closer we get to the launch date
Mcvee. These past few days have been your chance to sell your 100 shares and run buddy. I hope you did so we can all move on. Good luck to you!
Mcvee. These past few days have been your chance to sell your 100 shares and run buddy. I hope you did so we can all move on. Good luck to you!
The Pharma partner is "purchasing a stake" according to the PR, which I read as buying into the pet cgm for either a minority/majority/equal partnership on it. That alone has to be worth tens of millions if not hundreds right?
Followers
|
148
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13228
|
Created
|
10/05/09
|
Type
|
Free
|
Moderators |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |